Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Upwork Inc (UPWK) Price & Performance

Cassava Sciences IncTrade
Upwork IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Upwork Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Upwork Inc trades at $9.39 (market cap $1.14B). The key difference: Upwork Inc is far larger — about 21.5× Cassava Sciences Inc's market cap, and Upwork Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNAUPWK
Market Cap
$53.14M$1.14B
Sector
HealthIndustrials
52-Week High
$4.64$22.11
52-Week Low
$1.09$7.84
Enterprise Value
-$33.43M$939.82M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Upwork Inc

Upwork (UPWK) trades at $9.03, down 0.99% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported $787.78M revenue for 2025 with strong profitability margins (77.54% gross margin, 13.81% net margin) but has missed EPS estimates for three consecutive quarters. Recent developments include AI integration partnerships and board refreshment, though multiple law firms are investigating potential securities law violations following a 19% stock decline after Q1 2026 results.

The stock presents a mixed outlook with attractive valuation metrics (P/E 11.4, P/S 1.62) and analyst consensus target of $10.67 (18% upside), but faces near-term headwinds from earnings misses and legal investigations. Key risks include execution challenges in AI integration and competitive pressure in the gig economy space, while opportunities lie in the company's capital-light marketplace model and growing freelance adoption.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Upwork Inc

Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.

Read more on UPWK